Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 3 de 3
Filter
Add more filters










Database
Publication year range
1.
Heart Rhythm O2 ; 2(4): 347-354, 2021 Aug.
Article in English | MEDLINE | ID: mdl-34430940

ABSTRACT

BACKGROUND: Optimal overlap ratio remains unclear in point-by-point laser balloon (LB) ablation. OBJECTIVE: This study sought to determine the optimal overlap strategy with target energies on the acute and chronic outcomes in LB pulmonary vein (PV) isolation (PVI). METHODS: Consecutive 38 patients (148 PVs) with atrial fibrillation underwent the first-generation LB PVI with the following protocols based on the overlap ratios for each PV anterior/posterior wall: 50%/50% (13 patients [49 PVs], group A), 50%/25% (15 patients [60 PVs], group B), and 25%/25% (10 patients [39 PVs], group C). High energies (240-255 J: 12 W / 20 seconds, 8.5 W / 30 seconds), moderate energies (200-210 J: 10 W / 20 seconds, 7 W / 30 seconds), and low-to-moderate energies (low, 165-170 J: 5.5 W / 30 seconds, 8.5 W / 20 seconds) were targeted for left PV anterior walls, right PV anterior walls, and bilateral PV posterior walls, respectively. First-pass PVI, the other procedure-related data, and atrial tachyarrhythmia recurrences were analyzed. RESULTS: First-pass PVI rate per PV was higher in group A (94%) than in group B (88%) and group C (62%) (P < .001). All PVs were finally isolated. First-pass time, total LB PVI time, complications, and atrial tachyarrhythmia recurrences during a mean follow-up of 11 ± 5 months did not differ between the groups. A few residual gaps after first-pass LB ablations were found for PV anterior walls even in group A and group B. CONCLUSION: Sufficiently overlapped LB ablation promises a high rate of first-pass PVI without adverse outcomes. High energy could be required for PV anterior walls.

2.
Rinsho Byori ; 53(3): 234-8, 2005 Mar.
Article in Japanese | MEDLINE | ID: mdl-15839053

ABSTRACT

Serum tumor markers are invasive diagnostic tools for malignant tumors and have been commonly used for purposes of screening, prognosis and selection of treatments. In order to develop a new marker, gene expression analysis technologies such as DNA microarray, differential display, cDNA subtraction, and serial analysis of gene expression, which enable investigators to obtain comprehensive data with respect to gene-expression profiles, are progressing rapidly. Several studies have already demonstrated the usefulness of these techniques for identifying novel cancer-related genes and for classifying human cancers at the molecular level. However, significant differences between the abundance ratio of the mRNA transcript and the corresponding protein product are observed for many genes. Also, the protein level in serum is affected by many physiological conditions and related circumstances, not only by mRNA levels in the cell. Therefore, quantitative proteomics technology based on high-resolution two-dimensional gel electrophoresis and mass spectrometric analysis is being developed. One of our goals is the serological evaluation for the new candidate proteins derived from the information of the above transcriptome and/or proteome analysis as a tumor marker. In this report, I will discuss the practical process of the investigation with special regards to a new protein named ALCAN which has been studied through cDNA cloning, preparation of recombinant protein and monoclonal antibodies, construction of immune assay system, and clinical evaluation.


Subject(s)
Biomarkers, Tumor/blood , Cell Adhesion Molecules/blood , Neoplasm Proteins/blood , Neoplasms/diagnosis , Proteomics , Cloning, Molecular , GPI-Linked Proteins , Humans , Intercellular Signaling Peptides and Proteins , Neoplasms/genetics , Oligonucleotide Array Sequence Analysis , Prognosis , RNA, Messenger/blood
3.
Pediatr Int ; 46(2): 122-5, 2004 Apr.
Article in English | MEDLINE | ID: mdl-15056235

ABSTRACT

BACKGROUND: The efficacy of inactivated influenza vaccine in healthy infants and children younger than 24 months has not been confirmed. The aim of the present study was to determine the prophylactic effect of inactivated influenza vaccine against influenza A in healthy children aged 6-24 months. METHODS: Healthy infants and young children (6-24 months old) were immunized by subcutaneous injection of inactivated influenza vaccine before influenza seasons. Age matched children were randomly assigned as the control. These children were followed up from January to April in each year (2000, 2001 and 2002). The attack rates of influenza A infection was compared and statistically assessed. RESULTS: The attack rate of influenza A virus infection in the vaccine group and the control group were 14.8% (n = 27) vs 12.5% (n = 32) in 2000 (P = 0.526); 2.8% (n = 72) vs 7.2% (n = 69) in 2001 (P = 0.203); and 3.4% (n = 52) vs 8.9% (n = 56) in 2002 (P = 0.205). The attack rates of influenza A between the two groups were not significantly different. CONCLUSIONS: Inactivated influenza vaccine did not reduce the attack rate of influenza A infection in 6-24 month old children.


Subject(s)
Influenza A virus , Influenza Vaccines/therapeutic use , Influenza, Human/prevention & control , Child, Preschool , Female , Follow-Up Studies , Humans , Infant , Male , Treatment Failure , Vaccines, Inactivated/therapeutic use
SELECTION OF CITATIONS
SEARCH DETAIL
...